BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 20372154)

  • 1. Determinants of survival in patients with brain metastases from cutaneous melanoma.
    Staudt M; Lasithiotakis K; Leiter U; Meier F; Eigentler T; Bamberg M; Tatagiba M; Brossart P; Garbe C
    Br J Cancer; 2010 Apr; 102(8):1213-8. PubMed ID: 20372154
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic factors for overall survival after radiosurgery for brain metastases from melanoma.
    Marcus DM; Lowe M; Khan MK; Lawson DH; Crocker IR; Shelton JW; Melton A; Maynard N; Delman KA; Carlson GW; Rizzo M
    Am J Clin Oncol; 2014 Dec; 37(6):580-4. PubMed ID: 23428955
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stereotactic radiosurgery combined with nivolumab or Ipilimumab for patients with melanoma brain metastases: evaluation of brain control and toxicity.
    Minniti G; Anzellini D; Reverberi C; Cappellini GCA; Marchetti L; Bianciardi F; Bozzao A; Osti M; Gentile PC; Esposito V
    J Immunother Cancer; 2019 Apr; 7(1):102. PubMed ID: 30975225
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum S100B, lactate dehydrogenase and brain metastasis are prognostic factors in patients with distant melanoma metastasis and systemic therapy.
    Weide B; Richter S; Büttner P; Leiter U; Forschner A; Bauer J; Held L; Eigentler TK; Meier F; Garbe C
    PLoS One; 2013; 8(11):e81624. PubMed ID: 24312329
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Number of metastases, serum lactate dehydrogenase level, and type of treatment are prognostic factors in patients with brain metastases of malignant melanoma.
    Eigentler TK; Figl A; Krex D; Mohr P; Mauch C; Rass K; Bostroem A; Heese O; Koelbl O; Garbe C; Schadendorf D;
    Cancer; 2011 Apr; 117(8):1697-703. PubMed ID: 21472716
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Survival and prognostic factors in patients with brain metastases from malignant melanoma.
    Meier S; Baumert BG; Maier T; Wellis G; Burg G; Seifert B; Dummer R
    Onkologie; 2004 Apr; 27(2):145-9. PubMed ID: 15138346
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BRAF V600E mutation and BRAF kinase inhibitors in conjunction with stereotactic radiosurgery for intracranial melanoma metastases.
    Xu Z; Lee CC; Ramesh A; Mueller AC; Schlesinger D; Cohen-Inbar O; Shih HH; Sheehan JP
    J Neurosurg; 2017 Mar; 126(3):726-734. PubMed ID: 27203149
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multimodality treatment of melanoma brain metastases incorporating stereotactic radiosurgery (SRS).
    Samlowski WE; Watson GA; Wang M; Rao G; Klimo P; Boucher K; Shrieve DC; Jensen RL
    Cancer; 2007 May; 109(9):1855-62. PubMed ID: 17351953
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of prognostic factors in patients with brain metastases: a review of 1292 patients.
    Lagerwaard FJ; Levendag PC; Nowak PJ; Eijkenboom WM; Hanssens PE; Schmitz PI
    Int J Radiat Oncol Biol Phys; 1999 Mar; 43(4):795-803. PubMed ID: 10098435
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Survival and prognostic factors for patients with melanoma brain metastases in the era of modern systemic therapy.
    Tio M; Wang X; Carlino MS; Shivalingam B; Fogarty GB; Guminski AD; Lo S; Hong AM; Menzies AM; Long GV
    Pigment Cell Melanoma Res; 2018 Jul; 31(4):509-515. PubMed ID: 29277979
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The combination of stereotactic radiosurgery with immune checkpoint inhibition or targeted therapy in melanoma patients with brain metastases: a retrospective study.
    Martins F; Schiappacasse L; Levivier M; Tuleasca C; Cuendet MA; Aedo-Lopez V; Gautron Moura B; Homicsko K; Bettini A; Berthod G; Gérard CL; Wicky A; Bourhis J; Michielin O
    J Neurooncol; 2020 Jan; 146(1):181-193. PubMed ID: 31836957
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Malignant melanoma brain metastases: Treatment results and prognostic factors--a single-center retrospective study.
    Ostheimer C; Bormann C; Fiedler E; Marsch W; Vordermark D
    Int J Oncol; 2015; 46(6):2439-48. PubMed ID: 25891163
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metastatic melanoma: prognostic factors and survival in patients with brain metastases.
    Frinton E; Tong D; Tan J; Read G; Kumar V; Kennedy S; Lim C; Board RE
    J Neurooncol; 2017 Dec; 135(3):507-512. PubMed ID: 28819707
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Brain and leptomeningeal metastases from cutaneous melanoma: survival outcomes based on clinical features.
    Raizer JJ; Hwu WJ; Panageas KS; Wilton A; Baldwin DE; Bailey E; von Althann C; Lamb LA; Alvarado G; Bilsky MH; Gutin PH
    Neuro Oncol; 2008 Apr; 10(2):199-207. PubMed ID: 18287337
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ipilimumab and Stereotactic Radiosurgery Versus Stereotactic Radiosurgery Alone for Newly Diagnosed Melanoma Brain Metastases.
    Patel KR; Shoukat S; Oliver DE; Chowdhary M; Rizzo M; Lawson DH; Khosa F; Liu Y; Khan MK
    Am J Clin Oncol; 2017 Oct; 40(5):444-450. PubMed ID: 26017484
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic factors for survival in patients treated with stereotactic radiosurgery for recurrent brain metastases after prior whole brain radiotherapy.
    Caballero JA; Sneed PK; Lamborn KR; Ma L; Denduluri S; Nakamura JL; Barani IJ; McDermott MW
    Int J Radiat Oncol Biol Phys; 2012 May; 83(1):303-9. PubMed ID: 22079723
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact on overall survival of the combination of BRAF inhibitors and stereotactic radiosurgery in patients with melanoma brain metastases.
    Wolf A; Zia S; Verma R; Pavlick A; Wilson M; Golfinos JG; Silverman JS; Kondziolka D
    J Neurooncol; 2016 May; 127(3):607-15. PubMed ID: 26852222
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predicting survival in melanoma patients treated with concurrent targeted- or immunotherapy and stereotactic radiotherapy : Melanoma brain metastases prognostic score.
    Schaule J; Kroeze SGC; Blanck O; Stera S; Kahl KH; Roeder F; Combs SE; Kaul D; Claes A; Schymalla MM; Adebahr S; Eckert F; Lohaus F; Abbasi-Senger N; Henke G; Szuecs M; Geier M; Sundahl N; Buergy D; Dummer R; Guckenberger M
    Radiat Oncol; 2020 Jun; 15(1):135. PubMed ID: 32487100
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stereotactic radiosurgery combined with anti-PD1 for the management of melanoma brain metastases: A retrospective study of safety and efficacy.
    Carron R; Gaudy-Marqueste C; Amatore F; Padovani L; Malissen N; Balossier A; Loundou A; Bonnet N; Muracciole X; Régis JM; Grob JJ
    Eur J Cancer; 2020 Aug; 135():52-61. PubMed ID: 32535348
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Linac radiosurgery for brain metastasis of melanoma.
    Noël G; Simon JM; Valery CA; Cornu P; Boisserie G; Ledu D; Hasboun D; Tep B; Delattre JY; Marsault C; Baillet F; Mazeron JJ
    Stereotact Funct Neurosurg; 2002; 79(3-4):245-55. PubMed ID: 12890983
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.